tradmap

LCTX Lineage Cell Therapeutics, Inc.

$1.10 -0.90%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $278 million. Shares last traded at $1.10, 47.4% below their 52-week high. Over the past year the stock is down 10.6%. Net profit margin is -246.6%, below the peer median of 5.3%. Revenue grew 53.2% year over year.

Market Cap
$278M
Shares Out
252.9M
EPS (TTM)
$-0.52
P/E Ratio
P/S Ratio
21.26
P/B Ratio
4.57
Dividend / Share
Dividend Yield
52-Week High
$2.09
52-Week Low
$1.00
Volume
42,295
Avg Vol (3m)
68,954.778

Performance

1W
-5.98%
1M
-3.51%
3M
-9.47%
6M
-40.22%
YTD
-33.33%
1Y
-10.57%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
47.57
SMA (50)
$1.15
SMA (200)
$1.47
Price vs SMA50
-4.65%
Price vs SMA200
-25.19%
ATR (14)
$0.05

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$13M
Net Income
$-32M
Gross Margin
63.2%
Operating Margin
-205.2%
Net Margin
-246.6%
Return on Equity
-53.0%
Return on Assets
-30.4%
Current Ratio
6.61
Debt / Equity
0.76
Revenue Growth (YoY)
+53.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.06 2026-08-06
Q1 2026 $-0.03 2026-05-12
FY 2025 $-0.28 2026-03-05
Q3 2025 $-0.28 2025-11-06
Q2 2026 $-0.15 2026-08-06
Q1 2026 $-0.02 2026-05-12

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

LCTX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
21.26 / 19.49 med
+9% premium
Net margin vs peers
-246.6% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.